Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program.
about
Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012.In vitro activity of new cephalosporins vs Streptococcus pneumoniae from the Canadian Bacterial Surveillance Network: 2008-2011.PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates.High Throughput Screen Identifies Natural Product Inhibitor of Phenylalanyl-tRNA Synthetase from Pseudomonas aeruginosa and Streptococcus pneumoniae.Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from AustraliaIn vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance studyPenetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects.Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.).Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.Recent trends in resistance to cell envelope-active antibacterial agents among key bacterial pathogens.β-Lactam antimicrobials: what have you done for me lately?Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections.Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.The changing microbiologic epidemiology of community-acquired pneumonia.Recent Advances in the Rational Design and Optimization of Antibacterial Agents.Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers.Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010-2011.Community-onset bacteraemia of unknown origin: clinical characteristics, epidemiology and outcome.Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection.Ceftaroline versus isolates from animal bite wounds: comparative in vitro activities against 243 isolates, including 156 Pasteurella species isolates.Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance.Efficacy of Ceftaroline Fosamil against Escherichia coli and Klebsiella pneumoniae strains in a rabbit meningitis model.Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel.
P2860
Q33732529-5E71EF11-E25A-4AA7-8B93-34340E2F44F8Q34363461-7B9211F2-4C59-4215-A4A2-7D17AB0D8664Q34596507-820F2278-118F-4712-BB07-6C94DDD34A52Q35544892-D4DAFC74-7A2F-4665-A7B9-3C6D98B26FBEQ36290502-CDEFF21C-3073-433A-B035-F13B81A59F73Q37263425-41AB6848-54B1-48B4-B49B-3834EED6087FQ37287884-1661FA73-100D-4043-B369-EABB62C34832Q37364437-6AAFDC43-620B-4B10-9665-2C422B437206Q38025132-80C4B623-311A-417A-975F-566365800C70Q38076452-EB50BA9A-818C-49B1-BA29-6FAD55328C48Q38076453-B090EA8D-B233-46A9-9D90-EB59D2429342Q38088261-777B47FA-E7C8-4769-8863-053E565855DAQ38117077-3206275B-AB79-4F45-A8DA-379F2EEEB449Q38160635-665F4DA9-AD2D-4C03-BB6A-30B9313FDE11Q38958278-43D1112C-AE47-44F0-B65E-FBC7FA3C2925Q39682573-4AA67CAF-F4EA-4C20-9839-087D7AE3820BQ39766920-814DE424-12A1-43DC-BA3C-FA6AFFC09D48Q40204414-55DE3807-D8C0-4FCA-807F-26E74DCC2E99Q40804939-CC4C7D51-E592-484C-920B-214D475E1D16Q41182854-644CAFC8-8B6B-4AC0-80D0-BE2E8B4BC2BEQ41443468-21969218-4C98-4DCB-846D-2E302B227105Q41507443-6F705275-275B-4E7D-A0E8-3E4C9B2DBA7DQ42206236-1E6FFDD9-28CC-4675-9518-C04903C6F8C3Q42872142-E816D18E-0981-48DE-BF02-AE8219946863Q44796743-B8BF428B-E67D-4EFB-81F0-E0CD3315F552
P2860
Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Summary of ceftaroline activit ...... (AWARE) surveillance program.
@en
type
label
Summary of ceftaroline activit ...... (AWARE) surveillance program.
@en
prefLabel
Summary of ceftaroline activit ...... (AWARE) surveillance program.
@en
P2860
P356
P1476
Summary of ceftaroline activit ...... (AWARE) surveillance program.
@en
P2093
David J Farrell
Ronald N Jones
P2860
P304
P356
10.1128/AAC.00330-12
P407
P577
2012-04-02T00:00:00Z